Considering the critical role of angiogenesis in tumor progression and the need for multi-target therapies to overcome drug resistance, S1PR3 antagonism via pepducins presents a promising strategy, particularly in S1P-driven malignancies like OS. This evidence concerns the gene S1PR3 and neoplasm.